| Drug Type Small molecule drug | 
| Synonyms | 
| Action inhibitors, agonists | 
| Mechanism BTK inhibitors(Tyrosine-protein kinase BTK inhibitors), COX-2 inhibitors(Cyclooxygenase-2 inhibitors), μ opioid receptor agonists(Mu opioid receptor agonists) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePhase 1 | 
| First Approval Date- | 
| Regulation- | 
| Molecular FormulaC16H26ClNO2 | 
| InChIKeyPPKXEPBICJTCRU-XMZRARIVSA-N | 
| CAS Registry36282-47-0 | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Osteoarthritis | Phase 1 | United States  | 30 Jan 2022 | 





